Information about Binimetinib

Generic Name : Binimetinib
Up-to-date prescription details regarding Binimetinib are provided here.

Pronunciation : bin-i-ME-ti-nib

Learn the correct pronunciation of the Binimetinib, understand it's uses, recommended dosages, its indications, how to take, when to take, when not to take, side effects, special precautions, warnings and its and its storage instructions.

You will also find a list of the medication's International and Indian brand or trade names, as well as its pricing information. For verification of the information presented on this page or for additional clarifications, it's advisable to consult your doctor.

Therapeutic Classification : Chemotherapy

Trade Names/Brand Names of Binimetinib

India :

Mektovi

Overview of Binimetinib

Binimetinib tablets for oral use are prescribed in combination with encorafenib capsules for treating melanoma in adult patients. However, it should be used if the melanoma has a specific gene mutation.

Why is Binimetinib Prescribed? (Indications)

Binimetinib tablets are prescribed in combination with encorafenib for treating adult patients with a specific type of skin cancer known as melanoma which either cannot be removed by surgery or has moved to other parts of the body.

Binimetinib should be used to treat melanoma with a BRAF V600E or V600K gene mutation as confirmed by an FDA approved test.

When should Binimetinib not be taken? (Contraindications)

Binimetinib should not be used in patients-

• Allergic to binimetinib
• Pregnancy and breastfeeding

Binimetinib should not be used in children as safety and effectiveness of binimetinib has not been studied for their age groups.

Caution is required while treating patients with-

• Heart problems
• Liver disease
• Airway difficulties
• Eye disorders
• History of bleeding

What is the dosage of Binimetinib?

• The recommended adult dose of binimetinib is 45 mg taken two times a day in combination with encorafenib capsules.

• The dose of binimetinib can either be reduced or modified based on the side effects that occur in patients treated with binimetinib.

• Treatment with binimetinib can permanently be discontinued or stopped if the side effects are severe or life-threatening.

• Do not continue the treatment with binimetinib alone if encorafenib is withdrawn from the treatment schedule. The treatment with binimetinib should also be stopped.

How should Binimetinib be taken?

• Binimetinib tablets should be taken by mouth twice daily with a precise gap of 12 hours between the two doses.

• Binimetinib can be taken either with or without food. If gastric irritation occurs take binimetinib tablets with food.

• If a dose of binimetinib is missed, take the missed dose as early as possible. Do not take the missed dose if the next scheduled dose is close to 6 hours.

• Never take an extra dose if vomiting occurs while taking binimetinib tablets but continue with the next dose as per the next scheduled time.

What are the warnings and precautions for Binimetinib?

• Women of childbearing age should take effective contraceptive measures during the treatment with binimetinib and should continue that for at least 30 days after the last dose of binimetinib.

• Breastfeeding mothers should not breastfeed their children during binimetinib treatment and for at least three days after the last dose.

• Patients must confirm for the presence of BRAF V600E or V600K gene mutation with an FDA approved test before starting treatment with binimetinib.

• A MUGA (Multigated Acquisition) scan to find heart’s pumping function or an ECG should be taken before starting treatment with binimetinib, a month after treatment and continued every two or three months during the treatment.

• Blood clots can occur deep in the blood vessels while treating with binimetinib. Some clots can travel to the lungs resulting in blockade of blood supply to the lungs (i.e., Pulmonary embolism). In such situations, the dose of binimetinib can be reduced or treatment can be discontinued.

• Various eye disorders including new or worsening of visual disturbances can occur with binimetinib treatment; therefore patients should be advised to meet an eye specialist and to check their eye function at regular intervals.

• Airway disease including pneumonitis, heart problems, liver toxicity and severe muscle weakness may occur during binimetinib treatment. So, patients must be monitored for any signs and symptoms and should be treated accordingly.

• Bleeding events can occur during treatment with binimetinib and encorafenib combination. The most common place of bleeding is in stomach and worsening of bleeding in hemorrhoids or piles which require treatment modification.

What are the side effects of Binimetinib?

Gastrointestinal: Nausea, pain in the stomach, loose stools, vomiting, bleeding events in the stomach or rectum
Nervous system: Dizziness, fatigue or weakness
Eye: Visual disturbances, eye damage, blood clot in the eye
Cardiovascular system: High blood pressure
Skin: Rashes, bumps or painful nodules
Others: Anemia, fever, allergic reactions, low levels of sodium in the blood, increased levels of creatinine, creatinine phosphokinase, and liver enzymes

What are the other precautions for Binimetinib?

Women of childbearing age should perform a pregnancy test and must take binimetinib only when a pregnancy test shows negative.

What are the Drug Interactions of Binimetinib?

Patients should inform the doctor if they are taking any prescription, Over-The-Counter medicines or herbal supplements to avoid dangerous drug interactions.

What are the storage conditions for Binimetinib?

• Store binimetinib tablets at room temperature between 20°C and 25°C.

• Protect from excess moisture and heat.

• Keep binimetinib away from children and pets.